chronic hepatitis c

Summary

Summary: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.

Top Publications

  1. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  2. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
  3. ncbi Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Yasuhito Tanaka
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Nat Genet 41:1105-9. 2009
  4. pmc Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
    Robert E Lanford
    Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA
    Science 327:198-201. 2010
  5. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  6. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
  7. ncbi A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 38:518-26. 2003
  8. ncbi Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Laurent Castera
    Service d Hepato Gastroenterologie, Hopital Haut Leveque, C H U Bordeaux, Pessac, France
    Gastroenterology 128:343-50. 2005
  9. ncbi Adaptive immune responses in acute and chronic hepatitis C virus infection
    David G Bowen
    Center for Vaccines and Immunity, Columbus Children s Research Institute, Columbus, Ohio OH 43205, USA
    Nature 436:946-52. 2005
  10. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010

Detail Information

Publications345 found, 100 shown here

  1. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection...
  2. ncbi IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    Vijayaprakash Suppiah
    Storr Liver Unit, University of Sydney, Sydney, Australia
    Nat Genet 41:1100-4. 2009
    ..response (SVR) to PEG-IFN-alpha/RBV combination therapy in 293 Australian individuals with genotype 1 chronic hepatitis C, with validation in an independent replication cohort consisting of 555 individuals...
  3. ncbi Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Yasuhito Tanaka
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Nat Genet 41:1105-9. 2009
    The recommended treatment for patients with chronic hepatitis C, pegylated interferon-alpha (PEG-IFN-alpha) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all patients...
  4. pmc Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
    Robert E Lanford
    Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA
    Science 327:198-201. 2010
    ..The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance...
  5. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ..
  6. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  7. ncbi A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
    Chun Tao Wai
    Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 38:518-26. 2003
    Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients...
  8. ncbi Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Laurent Castera
    Service d Hepato Gastroenterologie, Hopital Haut Leveque, C H U Bordeaux, Pessac, France
    Gastroenterology 128:343-50. 2005
    ..We prospectively assessed the performance of FibroScan in patients with chronic hepatitis C, in comparison with and combined with currently available biochemical markers (Fibrotest; Biopredictive; ..
  9. ncbi Adaptive immune responses in acute and chronic hepatitis C virus infection
    David G Bowen
    Center for Vaccines and Immunity, Columbus Children s Research Institute, Columbus, Ohio OH 43205, USA
    Nature 436:946-52. 2005
    ....
  10. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010
    ..Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated...
  11. ncbi Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
    Laurent Sandrin
    Echosens, Paris, France
    Ultrasound Med Biol 29:1705-13. 2003
    ..of the technique, as well as its ability to quantify liver fibrosis, were evaluated in 106 patients with chronic hepatitis C. Liver elasticity measurements were reproducible (standardized coefficient of variation: 3%), operator-..
  12. pmc Interferon signaling and treatment outcome in chronic hepatitis C
    Magdalena Sarasin-Filipowicz
    Department of Biomedicine, University of Basel, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 105:7034-9. 2008
    ..The current standard therapy for chronic hepatitis C (CHC) consists of a combination of pegylated IFN alpha (pegIFNalpha) and ribavirin...
  13. ncbi Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    F Imbert-Bismut
    Department of Biochemistry, , Paris, France
    Lancet 357:1069-75. 2001
    ..60 to 1.00 (34% [115] of all patients). INTERPRETATION: A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection...
  14. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin.
  15. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..combined with either pegylated interferon (PegIFN) alpha2a or PegIFNalpha2b is the standard of care for chronic hepatitis C virus (HCV) infection...
  16. ncbi Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death.
  17. ncbi The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
    Heather M Patton
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA, USA
    J Hepatol 40:484-90. 2004
    ..Questions remain regarding the etiology of steatosis in hepatitis C, and its impact on disease progression and treatment outcomes...
  18. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C.
  19. ncbi Interferon therapy prolonged life expectancy among chronic hepatitis C patients
    Haruhiko Yoshida
    Department of Gastroenterology, University of Tokyo Graduate School of Medicine, Bunkyo, Tokyo, Japan
    Gastroenterology 123:483-91. 2002
    The effects of interferon therapy in chronic hepatitis C patients on survival are unclear. Our objective was to analyze survival among a large cohort of chronic hepatitis C patients.
  20. ncbi Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
    Xavier Forns
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatology 36:986-92. 2002
    Liver biopsy is required for staging hepatic fibrosis in patients with chronic hepatitis C, but it is an expensive procedure with occasional complications and poor patient acceptance...
  21. ncbi ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
    Jacques Fellay
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 464:405-8. 2010
    ..Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV...
  22. pmc Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection
    J R Vidal-Castineira
    Hospital Universitario Central de Asturias, Spain
    J Virol 84:475-81. 2010
    ..However, the KIR2DL3/KIR2DL3-HLA-C1C1 genotype clearly correlated with a satisfactory response to treatment, defined by the clearance of HCV RNA...
  23. pmc Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St Louis, MO 63110, USA
    N Engl J Med 359:2429-41. 2008
    In patients with chronic hepatitis C who do not have a response to antiviral treatment, the disease may progress to cirrhosis, liver failure, hepatocellular carcinoma, and death...
  24. ncbi Projecting future complications of chronic hepatitis C in the United States
    Gary L Davis
    Division of Hepatology, Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 9:331-8. 2003
    b>Chronic hepatitis C virus (HCV) infection is common and often results in slowly progressive liver disease...
  25. pmc Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity
    Pei Zhang
    Division of Hematology and Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:7537-41. 2009
    ..Our studies contribute to understanding the mechanisms of antibody-mediated neutralization and interference and provide a practical approach to the development of more potent and broadly reactive hepatitis C immune globulins...
  26. ncbi Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Insitute, and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, New South Wales, Australia
    Gastroenterology 125:1695-704. 2003
    b>Chronic hepatitis C virus infection is associated with an increased prevalence of type 2 diabetes. We hypothesized that virus-induced insulin resistance may be a mechanism for fibrogenesis in chronic hepatitis C virus infection.
  27. ncbi Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy
    H Yoshida
    Department of Gastroenterology, University of Tokyo, Japan
    Ann Intern Med 131:174-81. 1999
    ..Previous studies on the effect of interferon therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for hepatocellular carcinoma...
  28. ncbi Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    L E Adinolfi
    Internal Medicine and Hepatology, Second University of Naples, Naples, Italy
    Hepatology 33:1358-64. 2001
    The role of steatosis in the progression of liver damage in chronic hepatitis C (CHC) was studied. Enrolled were 180 consecutive liver biopsy-proven CHC patients and 41 additional subjects with a known duration of infection...
  29. ncbi [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]
    Heon Ju Lee
    Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
    Korean J Hepatol 14:46-57. 2008
    ..compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-alpha) and ribavirin, according to the treatment duration in Korean patients with chronic hepatitis C.
  30. ncbi Natural history and predictors of disease severity in chronic hepatitis C
    Julien Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 44:S19-24. 2006
    Cirrhosis is the end-stage consequence of fibrosis progression in patients with chronic hepatitis C. The median time from infection to cirrhosis is 30 years, with a high inter-individual variability, which is now better understood...
  31. ncbi Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C
    Alessio Aghemo
    A M Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Via F Sforza 35, 20122 Milan, Italy
    Nat Rev Gastroenterol Hepatol 7:485-94. 2010
    ..We have, therefore, scrutinized the design and conduct of all available studies to unravel the reasons behind the therapeutic differences between PEG-IFN-alpha2a and PEG-IFN-alpha2b...
  32. ncbi Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
    Galia Askarieh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    Hepatology 51:1523-30. 2010
    ..High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP-10 on the reduction of ..
  33. ncbi Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients
    Masahiko Ito
    Department of Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashi Murayama shi, Tokyo 208 0011, Japan
    Clin Immunol 135:459-65. 2010
    Epidemiological data indicate a close relationship between chronic hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphoma (B-NHL), suggesting that chronic HCV infection is, at least in part, associated with B-lymphomagenesis...
  34. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  35. ncbi Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
    Heiner Wedemeyer
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:3447-58. 2002
    ..Thus, the defective functions of HCV-specific CD8+ T cells might contribute to viral persistence in chronically infected patients, and knowledge on their reversibility may facilitate the development of immunotherapeutic vaccines...
  36. ncbi The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection
    M Zeremski
    Division of Gastroenterology and Hepatology, Department of Medicine, and The Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York 10021, USA
    J Viral Hepat 14:675-87. 2007
    ..While peripheral blood and intrahepatic levels of all of these chemokines are elevated in chronic hepatitis C patients, only select chemokines have been found to be correlated with hepatic inflammation...
  37. ncbi Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression
    Hla Hla Thein
    University Health Network, Division of Clinical Decision Making and Health Care Research, Toronto, Ontario, Canada
    Hepatology 48:418-31. 2008
    Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage-specific fibrosis progression rates and their determinants in these individuals...
  38. ncbi Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada
    Gastroenterology 128:1437-44. 2005
    Pegylated interferon (IFN)-alpha plus ribavirin is the most effective treatment of chronic hepatitis C but has unpleasant side effects and high costs. A large proportion of patients do not respond to therapy for reasons that are unclear...
  39. ncbi Treatment of chronic hepatitis C in southern Taiwan
    Wang Long Chuang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University, No 100 Shih chuan 1st Road, Kaohsiung 807, Taiwan, ROC
    Intervirology 49:99-106. 2006
    b>Chronic hepatitis C virus (HCV) infection may lead to cirrhosis and hepatocellular carcinoma. Interferon (IFN)-alpha is effective in the treatment of chronic hepatitis C. The rate of response to IFN is enhanced by increasing the IFN dose...
  40. ncbi Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C
    Kirti Shetty
    Division of Transplantation, Georgetown University Hospital, Washington, DC 20007, USA
    Liver Transpl 14:534-40. 2008
    ..Occult HBV infection is strongly associated with the presence of anti-HBc, history of injection drug use, and explant-proven HCC...
  41. pmc Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC)...
  42. ncbi Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C
    Ian Homer Y Cua
    Storr Liver Unit, Westmead Millennium Institute and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia
    Hepatology 48:723-31. 2008
    The interaction between insulin resistance (IR), steatosis and genotype to fibrosis in chronic hepatitis C virus (HCV) infection has not been comprehensively assessed...
  43. ncbi Treatment of chronic hepatitis C in Asia: when East meets West
    Ming Lung Yu
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    J Gastroenterol Hepatol 24:336-45. 2009
    The issue of best treatment for chronic hepatitis C virus (HCV) infection is in constant flux, not only in Western countries but also in Asia. Currently, pegylated-interferon plus ribavirin is the standard of care...
  44. pmc Expert opinion on the treatment of patients with chronic hepatitis C
    S Zeuzem
    Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    J Viral Hepat 16:75-90. 2009
    ....
  45. ncbi Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6
    N H Nguyen
    Pacific Health Foundation, San Jose, CA, USA
    J Viral Hepat 17:691-7. 2010
    b>Chronic hepatitis C is generally underappreciated in Asian Americans, and most pivotal studies were conducted in western countries and only included a small numbers of Asian patients...
  46. ncbi Natural history of chronic hepatitis C virus infection
    Antonio Ascione
    Unità a struttura complessa di Epatologia, Azienda Ospedaliera di rilievo nazionale e di alta specializzazione A Cardarelli, Napoli, Italy
    Dig Liver Dis 39:S4-7. 2007
    The natural history of chronic Hepatitis C Virus (HCV) infection is still poorly understood. The main reason is the asymptomatic onset and course in the majority of infected subjects...
  47. ncbi Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis
    M Clemente
    Liver Research Unit, University Hospital Santa Cristina, Madrid, Spain
    J Viral Hepat 13:625-32. 2006
    ..Our aim was to evaluate whether endoglin may be associated with hepatic fibrosis featuring chronic hepatitis C virus (HCV) infection...
  48. ncbi Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores
    Laurent Castera
    Service d Hepato Gastroenterologie, Hopital Haut Leveque, Centre Hospitalier Universitaire CHU de Bordeaux, Pessac, France
    J Hepatol 50:59-68. 2009
    ..of transient elastography (TE, FibroScan) for the detection of cirrhosis and oesophageal varices (OV) in chronic hepatitis C (CHC), as compared with currently available non-invasive methods (AST/ALT ratio (AAR), APRI, prothrombin ..
  49. ncbi Sampling variability of liver fibrosis in chronic hepatitis C
    Pierre Bedossa
    Service d Anatomie Pathologique, Hopital Bicetre, Le Kremlin Bicetre, France
    Hepatology 38:1449-57. 2003
    Fibrosis is a common endpoint of clinical trials in chronic hepatitis C, and liver biopsy remains the gold standard for fibrosis evaluation. However, variability in the distribution of fibrosis within the liver is a potential limitation...
  50. ncbi A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C
    Hongjin Huang
    Celera Diagnostics, Alameda, CA 94502, USA
    Hepatology 46:297-306. 2007
    ..progression to cirrhosis but cannot accurately predict the risk of developing cirrhosis in patients with chronic hepatitis C (CHC). The aim of this study was to develop a predictive signature for cirrhosis in Caucasian patients...
  51. pmc Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C
    Sonu Dhillon
    Department of Medicine, Rush University Medical Center, Ste 158 Professional Building, Chicago, IL 60612, USA
    Dig Dis Sci 55:1785-90. 2010
    ....
  52. ncbi Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group
    J G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    J Gastroenterol Hepatol 15:945-51. 2000
    b>Chronic hepatitis C is a slowly progressing inflammatory disease of the liver that can lead to cirrhosis and its complications. Assessment of liver damage in hepatitis C has been primarily via histological evaluation...
  53. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C.
  54. ncbi Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
    Peter Simmonds
    Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    Hepatology 42:962-73. 2005
    ..In conclusion, these proposals provide the framework by which the HCV databases store and provide access to data on HCV, which will internationally coordinate the assignment of new genotypes and subtypes in the future...
  55. ncbi Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials
    Tahany Awad
    Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Center for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Hepatology 51:1176-84. 2010
    ..interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines...
  56. ncbi Estimating progression to cirrhosis in chronic hepatitis C virus infection
    A J Freeman
    Viral Hepatitis Research, Gastrointestinal and Liver Unit, The Prince of Wales Hospital, Sydney, Australia
    Hepatology 34:809-16. 2001
    To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies that incorporated assessment for cirrhosis ..
  57. ncbi Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
    Antonio Ascione
    Department of Gastroenterology, Liver Unit, Cardarelli Hospital, Napoli, Italy
    Gastroenterology 138:116-22. 2010
    Patients with chronic hepatitis C virus (HCV) infection are frequently treated with a combination of pegylated interferon (peginterferon) and ribavirin...
  58. ncbi Oxidative stress in chronic hepatitis C: not just a feature of late stage disease
    Sanjiv K Jain
    The Liver Unit, Manchester Royal Infirmary, Manchester, UK
    J Hepatol 36:805-11. 2002
    b>Chronic hepatitis C infection is a major world-wide problem, frequently progressing to cirrhosis, liver failure or hepatoma. The pathological mechanisms of disease progression are unclear but oxidant stress may play a role.
  59. ncbi T(14;18) translocation in chronic hepatitis C virus infection
    A L Zignego
    Department of Internal Medicine, University of Florence, School of Medicine, 50134 Florence, Italy
    Hepatology 31:474-9. 2000
    Pathogenic mechanisms of B-cell lymphoproliferative disorders in chronic hepatitis C virus (HCV) infection are unclear...
  60. ncbi Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome
    Anouk T Dev
    Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
    Hepatology 36:1259-65. 2002
    ..This study also supports the concept that race and ethnicity are important determinants of treatment outcome in HCV infected patients...
  61. pmc Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
    Herbert L Bonkovsky
    Liver Biliary Pancreatic Center and the Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
    J Hepatol 46:420-31. 2007
    ..This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial...
  62. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    Interferon-based regimens for the treatment of chronic hepatitis C have become increasingly effective and are able to eradicate virus in more than one half of cases...
  63. ncbi Natural history of chronic hepatitis C
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, USA
    Hepatology 36:S35-46. 2002
    ..Others regard chronic hepatitis C as having a variable outcome, the majority of infected persons not dying from the disease, but more likely ..
  64. ncbi Diagnosis, management, and treatment of hepatitis C
    Doris B Strader
    Fletcher Allen Health Care University of Vermont College of Medicine, Burlington, VA, USA
    Hepatology 39:1147-71. 2004
  65. ncbi Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection
    Yves Horsmans
    Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Unit de Pharmacologie Clinique, Brussels, Belgium
    Hepatology 42:724-31. 2005
    Immune-based therapy is the mainstay treatment for chronic hepatitis C virus (HCV) infection but causes multiple side effects and achieves durable viral clearance in only approximately 50% of patients...
  66. ncbi Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography
    Ryota Masuzaki
    Department of Gastroenterology, University of Tokyo, Tokyo, Japan
    Hepatology 49:1954-61. 2009
    ..measurement (LSM) as a predictor of hepatocellular carcinoma (HCC) development among patients with chronic hepatitis C. Between December 2004 and June 2005, a total of 984 HCV-RNA positive patients, without HCC or a past ..
  67. pmc Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy
    Milton W Taylor
    Department of Biology, Indiana University, Bloomington, IN 47401, USA
    J Virol 81:3391-401. 2007
    Treating chronic hepatitis C virus (HCV) infection using pegylated alpha interferon and ribavirin leads to sustained clearance of virus and clinical improvement in approximately 50% of patients...
  68. pmc Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C
    L Fartoux
    Service d Hepatologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Gut 54:1003-8. 2005
    Insulin resistance is a frequent feature of chronic hepatitis C. Whether insulin resistance could be the cause or consequence of steatosis and fibrosis is unknown...
  69. ncbi Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Hepatology 49:22-31. 2009
    Although two pegylated interferons (Peg-IFN) are available to treat chronic hepatitis C virus (HCV) infection, no head-to-head comparative studies have been published...
  70. ncbi Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial
    Donald M Jensen
    Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Ann Intern Med 150:528-40. 2009
    Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin.
  71. ncbi Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors
    Sharif B Missiha
    Division of Gastroenterology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 134:1699-714. 2008
    The hepatic complications of chronic hepatitis C (CHC) usually occur only after progression to cirrhosis has taken place...
  72. ncbi In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
    ..chronic HCV infection, we investigated ER stress and the UPR in liver samples from untreated patients with chronic hepatitis C (CHC), in comparison with normal livers...
  73. ncbi Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
    Manuel Romero-Gomez
    Unit for the Clinical Management of Digestive Diseases and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Universitario de Valme, Sevilla, Spain
    Hepatology 50:1702-8. 2009
    Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, ..
  74. ncbi Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1
    Salvatore Petta
    Dipartimento Biomedico di Medicina Interna e Specialistica, Cattedra di Gastroenterologia, DiBiMIS, Palermo, Italy
    Hepatology 52:1543-52. 2010
    Metabolic factors have been associated with liver damage in patients with genotype 1 chronic hepatitis C (G1 CHC)...
  75. ncbi Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Sharif Missiha
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 102:2181-8. 2007
    ..The lower response rate of African-Americans relative to whites has been previously described, but studies of other racial or ethnic groups remain limited...
  76. pmc Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner
    Golo Ahlenstiel
    Immunology Section, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 138:325-35.e1-2. 2010
    Patients with chronic hepatitis C virus (HCV) infection display great variability in disease activity and progression...
  77. ncbi Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
    Martin Lagging
    Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
    Hepatology 47:1837-45. 2008
    Previous trials investigating the efficacy of treatment durations shorter than the standard of 24 weeks for chronic hepatitis C virus (HCV) genotype 2/3 infections have yielded discordant results...
  78. pmc Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Tania Mara Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 49:1847-58. 2009
    ..with pegylated-interferon-alpha (PEG IFN-alpha) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients...
  79. pmc Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C
    Marc G Ghany
    Department of Health and Human Services, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 138:136-46. 2010
    Predictors of clinical outcomes and histologic progression among patients with chronic hepatitis C and advanced fibrosis are poorly defined. We developed statistical models to predict clinical and histologic outcomes in such patients.
  80. ncbi Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas
    V Paradis
    Service d'Anatomie Pathologique, , , France
    Hum Pathol 32:327-32. 2001
    ..in the pathogenesis of liver cirrhosis, we looked for replicative senescence cells in normal livers, chronic hepatitis C, and hepatocellular carcinoma (HCC)...
  81. ncbi Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection
    Mei Shu Lai
    Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
    Hepatology 43:1295-302. 2006
    ..In conclusion, in an area with a high prevalence of hepatitis virus infection, type 2 diabetes increases the risk of developing HCC in those who are HCV negative or have a high level of total cholesterol...
  82. ncbi A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
    Mark G Swain
    Health Research Innovation Center, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 139:1593-601. 2010
    ..Although small studies have reported that the SVR is durable and lasts for long periods, it has not been conclusively shown...
  83. ncbi Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease
    Arantxa Apolinario
    Hepatology Unit, University Hospital Santa Cristina, Madrid, Spain
    Am J Gastroenterol 97:2861-70. 2002
    Although chemokines seem to be important in certain inflammatory disorders, little is known about the role of these proteins in chronic hepatitis C.
  84. ncbi Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis
    Andrew D Clouston
    School of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Hepatology 41:809-18. 2005
    The mechanisms for progressive fibrosis and exacerbation by steatosis in patients with chronic hepatitis C (HCV) are still unknown...
  85. ncbi Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C
    Chung Feng Huang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    J Infect Dis 201:751-9. 2010
    ..The present study evaluated the efficacy and safety of pegylated interferon (PegIFN)/ribavirin treatment in elderly patients with hepatitis C virus (HCV) infection...
  86. pmc Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC).
  87. ncbi Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT
    Maxime Ronot
    Unit for Training and Research in Medicine, Universite Paris 7 Denis Diderot, Paris, France
    Radiology 256:135-42. 2010
    To prospectively assess the utility of perfusion computed tomography (CT) for differentiating minimal from intermediate fibrosis in treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
  88. ncbi Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results
    Monica Lupsor
    Department of Ultrasonography, University of Medicine and Pharmacy, 19 21 Croitorilor Str Cluj Napoca, Romania
    J Gastrointestin Liver Dis 18:303-10. 2009
    ..The current study aims to evaluate the performance of a new elastographic method (ARFI) in noninvasive fibrosis assessment and to compare it to another validated technology (transient elastography, TE)...
  89. pmc Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C
    Stephen E Livingston
    Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium Liver Disease and Hepatitis Program, Anchorage, Alaska 99508, USA
    Can J Gastroenterol 24:445-51. 2010
    Various factors influence the development and rate of fibrosis progression in chronic hepatitis C virus (HCV) infection.
  90. ncbi Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin
    Yasuko Murakami
    Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectural University, Okayama 719 1197, Japan
    J Nutr Sci Vitaminol (Tokyo) 53:213-8. 2007
    We investigated the effects of zinc supplementation on clinical observations in chronic hepatitis C patients receiving pegylated interferon (PEG-IFN) alpha-2b plus ribavirin combination therapy...
  91. ncbi Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient
    Maria Cubero
    Liver Unit, Department of Medicine, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Virology 370:237-45. 2008
    ..increasing number of new hepatitis C virus NS3-protease inhibitors are being evaluated for the treatment of chronic hepatitis C. Treatment-induced selection of mutants conferring resistance to protease inhibitors has been shown both in ..
  92. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
    ..We sought to determine if the IFN-lambda gene variant was also associated with serum lipid levels in chronic hepatitis C patients...
  93. ncbi Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan
    J F Huang
    Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    Aliment Pharmacol Ther 25:1029-37. 2007
    The long-term benefits of interferon-based therapy on preventing cirrhosis at non-cirrhotic stage in chronic hepatitis C patients are not fully clarified.
  94. ncbi Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C
    Wang Sheng Ko
    Department of Food and Nutrition, Hung Kuang University, Taichung, Taiwan, China
    World J Gastroenterol 11:4697-702. 2005
    To assess the extent of micronutrient and oxidative stress in blood and to examine their linkages with viral loads in chronic hepatitis C patients.
  95. ncbi Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
    Khoa D Lam
    Pacific Health Foundation, San Jose, CA, USA
    Hepatology 52:1573-80. 2010
    ..07 and P = 0.02)...
  96. ncbi Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C
    Shinya Maekawa
    First Department of Internal Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409 3898, Japan
    J Gastroenterol 44:1009-15. 2009
    ..Even with the recent combination therapy of peginterferon plus ribavirin for chronic hepatitis C, viral response is variable, and only half of treated patients could clear the virus [sustained viral ..
  97. ncbi Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance
    Kerry Lee Milner
    Garvan Institute for Medical Research, University of New South Wales 2010, Sydney, Australia
    Gastroenterology 138:932-41.e1-3. 2010
    b>Chronic hepatitis C (CHC) is associated with insulin resistance (IR), liver steatosis (genotype 3), and increased diabetes risk. The site and mechanisms of IR are unclear.
  98. ncbi Lymphoproliferative disorders in chronic hepatitis C
    R Idilman
    Department of Medicine, Division of Gastroenterology and Liver Transplantation, Loyola University Medical Center, Maywood, IL, USA
    J Viral Hepat 11:302-9. 2004
    b>Chronic hepatitis C virus (HCV) infection is associated with the development of lymphoproliferative disorders (LPDs)...
  99. ncbi Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C
    Konstantinos C Thomopoulos
    Department of Internal Medicine, University Hospital, Patras, Greece
    Eur J Gastroenterol Hepatol 17:149-53. 2005
    Hepatic steatosis is a common feature of chronic hepatitis C. The purpose of this study was to determine factors related to the presence of steatosis and to define the role of steatosis in the response to antiviral treatment in chronic ..
  100. ncbi Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C
    Takashi Honda
    Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Liver Int 30:527-37. 2010
    The aim of this study was to evaluate the efficacy and indication of combination therapy with ribavirin plus peginterferon-alpha-2b in chronic hepatitis C virus (HCV) patients aged 65 years and older.
  101. ncbi Metabolic syndrome, insulin resistance and adiponectin level in patients with chronic hepatitis C
    Mircea Grigorescu
    3rd Medical Clinic, University of Medicine and Pharmacy, Croitorilor Street 19 21, Cluj Napoca, Romania
    J Gastrointestin Liver Dis 17:147-54. 2008
    To assess insulin resistance and adiponectin profile in patients with chronic hepatitis C (CHC), according to the presence or absence of metabolic syndrome (MS).

Research Grants73

  1. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    b>Chronic hepatitis C is the leading cause of chronic liver disease and cirrhosis in the United States and is now the leading cause for liver transplantation due to end-stage liver disease. Approximately 1...
  2. Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)
    Peter Friedmann; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The co-occurrence of chronic hepatitis C virus (HCV) infection, drug dependence and psychiatric disorders is one of the greatest public health challenges to the incarcerated population...
  3. Natural History and Prevention of Viral Hepatitis Among Alaska Natives
    BRIAN JAMES MCMAHON; Fiscal Year: 2013
    ..11] In addition to chronic HBV, other chronic liver disease etiologies including chronic hepatitis C, non- alcoholic fatty liver disease and autoimmune hepatitis have been shown to cause substantial morbidity ..
  4. Ubiquitous pollutant acrolein inhibits IFN?? antiviral signaling: relevance to HC
    Swati Joshi-Barve; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Chronic Hepatitis C virus (HCV) infection remains a global health concern with nearly 200 million carriers worldwide...
  5. Heat Shock Protein Synthesis Inhibitor Treatment of Hepatitis C Viral Infection
    SAMUEL WHEELER FRENCH; Fiscal Year: 2013
    ..will test the clinical feasibility of the heat shock protein synthesis inhibitor Quercetin on patients with chronic hepatitis C viral infection through a phase I trial...
  6. Androgen Receptor Pathway and Risk of Hepatic Fibrosis in Hepatitis C
    DONNA LORRAINE WHITE; Fiscal Year: 2013
    ..increased risk of advanced liver disease based on results of blood tests in male veterans with chronic hepatitis C infection...
  7. Detection of Liver Fibrosis Using IVIM Diffusion and DCE MRI in HCV
    Bachir Taouli; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): There is an expected increased incidence of chronic hepatitis C virus infection (HCV) in the Unites States within the next years, with subsequent increased risks of liver damage, including fibrosis ..
  8. Hepatocarcinogenesis Secondary to Hepatitis C
    Srikanta Dash; Fiscal Year: 2012
    ..This research will potentially leads to an innovative therapeutic strategy for chronic hepatitis C patients not responding to interferon therapy...
  9. MECHANISMS OF LIVER INJURY BY HEPATITIS C AND ALCOHOL
    Steven A Weinman; Fiscal Year: 2013
    ..We also observed decreased FOXO3 activity in liver biopsies from chronic hepatitis C patients and abnormally localized FOXO3 in 85% of HCV-associated hepatocellular carcinomas...
  10. Hepatitis C virus and liver fibrogenesis
    Gulam Waris; Fiscal Year: 2010
    ..The mechanisms underlying the liver injury and fibrosis in chronic hepatitis C are unclear...
  11. Murine Model of HCV-Associated Human Liver Cancer
    Lishan Su; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection is now the leading cause of hepatocellular carcinoma (HCC), a highly lethal cancer with rapidly increasing incidence in the U.S...
  12. Listeria-Based Therapeutic Cancer Vaccine for Melanoma
    Dirk G Brockstedt; Fiscal Year: 2011
    ..were dosed safely with up to 1 x 109 live-attenuated bacteria for the treatment of advanced cancers and chronic hepatitis C infections...
  13. Mechanism of murine coronavirus induced hepatitis
    Susan R Weiss; Fiscal Year: 2010
    ..b>Chronic hepatitis C and hepatitis B virus infections in humans result in liver damage, inflammation, and secondary development ..
  14. HCV in Alcoholics
    Jack R Wands; Fiscal Year: 2011
    b>Chronic hepatitis C (HCV) infection is a major cause of liver disease, cirrhosis, and hepatocellular carcinoma (HCC) in alcoholics...
  15. Intracellular immunization strategy in inhibit HCV related liver cancer
    Srikanta Dash; Fiscal Year: 2010
    ..Public Health Relevance: Chronic hepatitis C virus infection accounts for 27% of liver cancer in the United States...
  16. Regulation of hepcidin and iron metabolism in liver disease
    Julia Goodnough; Fiscal Year: 2011
    ..Broadly, this study proposes to investigate the molecular etiology of iron overload that accompanies chronic hepatitis C (CMC) and alcoholic liver disease...
  17. Functional attributes of CD8+ T cells in recovery of hepatitis C virus infection
    HUGO RAMON ROSEN; Fiscal Year: 2013
    ..Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003 Apr;9(4):331-8 Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP...
  18. Effects of Ethanol on Proteasome-HCV Core Protein Interactions
    NATALIA ALEKSANDR OSNA; Fiscal Year: 2010
    ..We envision that this research will potentially have therapeutic applications, helping to improve chronic hepatitis C treatment and vaccine development
  19. Hepatitis C and Tumor Suppressors in Hepatocellular
    Stanley M Lemon; Fiscal Year: 2011
    ..probes in laser scanning confocal and multi photon microscopy studies of liver tissue from patients with chronic hepatitis C, and ask whether the abundance and cellular localization of pRb, p53, DDXS, or DDXS is altered in infected ..
  20. Role for tissue-type plasminogen activator in suppression of hepatic fibrosis
    Liang I Kang; Fiscal Year: 2013
    ..With the dramatic increased prevalence of non-alcoholic fatty liver disease and chronic hepatitis C worldwide, it is expected that the health care impact and cost of liver cirrhosis will dramatically ..
  21. Comparative Effectiveness of Advanced Diagnostic Imaging for Hepatic Fibrosis
    Jayant A Talwalkar; Fiscal Year: 2010
    ..quantitative elasticity imaging techniques, serum marker panels, and liver biopsy among 150 subjects with chronic hepatitis C, nonalcoholic fatty liver disease, and alcoholic liver disease...
  22. Role of HCV Sequence Variation in Pathology
    John E Tavis; Fiscal Year: 2010
    b>Chronic Hepatitis C virus (HCV) infection causes hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma. The factors governing the rate of disease progression along this spectrum of pathology are not known...
  23. Persistent hepatitis C virus replication and T cell immunity in pregnancy
    Christopher M Walker; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection is characterized by stable lifelong viremia and a substantially increased risk of serious progressive liver disease...
  24. Cost-effective Uses of New Hepatitis C Treatments and their VA Budgetary Impact
    Douglas K Owens; Fiscal Year: 2013
    ..We will develop a spreadsheet-based tool for direct use by VA policymakers to help them to anticipate and plan for the optimal roll-out and management of HCV treatments. ..
  25. Drug and Viral Induced Thyroiditis and Diabetes
    Yaron Tomer; Fiscal Year: 2013
    ..goal is to dissect the mechanisms underlying the development of thyroiditis and diabetes in patients with chronic hepatitis C virus (HCV) infection in order to design new treatment and prevention modalities. Nearly 2...
  26. Inflammation, Stress, and Social Behavior: Using Ecological Assessments and Model
    Charles Raison; Fiscal Year: 2012
    ..To test these hypotheses, 120 subjects with chronic hepatitis C virus infection will be randomized to receive treatment with pegylated IFN-alpha plus ribavirin or to ..
  27. Patient-Oriented Research on Hepatitis in Special Populations
    Raymond T Chung; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Chronic hepatitis C and B are important and growing causes of morbidity and mortality in the United States...
  28. Renal and Cardiovascular Events in Patients with Chronic Kidney Disease
    Akinlolu O Ojo; Fiscal Year: 2013
    ..initiate two new research projects namely: (a) The Epidemiology and Clinical Outcomes of CKD Patients with Chronic Hepatitis C (HCV) Infection;and (b) The Prevention of Kidney Disease in Liver Transplantation...
  29. Efficacy &safety of baclofen to reduce alcohol use in veterans with HCV
    Peter Hauser; Fiscal Year: 2013
    ..of Baclofen to Reduce Alcohol Use in Veterans with HCV BACKGROUND: Studies suggest the prevalence of chronic hepatitis C (HCV) among veterans treated within the Veterans Affairs Medical Centers (VAMCs) is 3 to 4 times greater ..
  30. Hepatitis C Clinical Trial-Clinical Center
    Jules L Dienstag; Fiscal Year: 2009
    Patients with chronic hepatitis C who do not respond to antiviral treatment are at risk of progression to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death...
  31. Micro-RNA 122 and Chronic Hepatitis C
    Stanley M Lemon; Fiscal Year: 2013
    ..miRNA is essential for replication of infectious HCV and thus plays a novel role in the pathogenesis of chronic hepatitis C. Recent chimpanzee studies have validated miR-122 silencing as an effective antiviral strategy, yet how miR-..
  32. Characterizing Alcohol's Effects on Repair of Liver Injury
    ANNA MAE ELIZABETH DIEHL; Fiscal Year: 2010
    ..g., nonalcoholic fatty liver disease - NAFLD) but accelerates the evolution of cirrhosis in others (e.g., chronic hepatitis C - HCV)...
  33. Interactions Between Hepatitis C and Serum Lipid Homeostasis
    KATHLEEN COREY; Fiscal Year: 2010
    ..b>Chronic hepatitis C (CHC) infection leads to decompensated liver failure, hepatocellular carcinoma and is the most common ..
  34. Role of HCV p7 and NS2 in infectious virus production
    Charles M Rice; Fiscal Year: 2012
    ..individuals at risk for the development of cirrhosis, hepatocellular carcinoma, and liver failure, making chronic hepatitis C the leading indication for liver transplantation...
  35. Persistent hepatitis C virus replication and T cell immunity in pregnancy
    Christopher M Walker; Fiscal Year: 2011
    b>Chronic hepatitis C virus (HCV) infection is characterized by stable life long viremia and a substantially increased risk of serious progressive liver disease. HCV persists in part because T cell immunity fails...
  36. An Adherence and Depression Intervention for Patients During Hepatitis C Therapy
    Donna M Evon; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Chronic hepatitis C viral (HCV) infection affects nearly 4 million Americans, leading to advanced liver damage and cancer, ..
  37. HCV genetic variation and hepatocellular carcinoma
    John E Tavis; Fiscal Year: 2012
    b>Chronic Hepatitis C virus (HCV) infection causes hepatitis and hepatocellular carcinoma (HCC)...
  38. Patient self-management and gene guided therapy for CHC
    Donald E Bailey; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Treatment for chronic hepatitis C (CHC) will undergo a dramatic change this year when a new blood test for a genetic polymorphism near the interleukin 28B (IL28B) gene and two newly approved protease ..
  39. Role of the inflammasome in hepatitis C virus pathogenesis
    Gulam Waris; Fiscal Year: 2012
    ..fundamental knowledge that will potentially help design the alternate strategies in the treatment of chronic hepatitis C infection...
  40. Amino Acid Transporters ASCT2 and LAT1 in Human Hepatocellular Cancer Growth
    BARRIE BODE; Fiscal Year: 2009
    ..The incidence of HCC is on the rise in the United States due primarily to the increasing prevalence of chronic hepatitis C infection, and there are currently limited treatment options for this recalcitrant malignancy...
  41. Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
    Zhilei Chen; Fiscal Year: 2010
    ..b>Chronic hepatitis C is the leading cause for liver transplantation...
  42. Preparing for New Antivirals: Preferences for Treatment of Hepatitis C
    Liana Fraenkel; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Project Summary Chronic hepatitis C (HCV) is a major healthcare burden among American veterans...
  43. A phase I/II trial of silymarin for chronic liver diseases
    RAJENDER KUCHIKULLA REDDY; Fiscal Year: 2010
    INTRODUCTION: This study will explore the potential role of silymarin (Sm) in patients with chronic hepatitis C (HCV). The majority of HCV patients are unresponsive to interferon-alfa (IFN?) based therapy...
  44. Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
    Brian R Edlin; Fiscal Year: 2013
    ..separate care. Chronic hepatitis C is the number one cause of chronic liver disease and liver cancer in most of the Western world...
  45. Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virus
    Andrew W Tai; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection develops in 70-80% of all exposed individuals and affects 3% of the world's population...
  46. A Novel Cultue System for Hepatitis C Virus
    Arielle Klepper; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection afflicts about 3 million people in the United States and is the leading indication for liver transplantation (CDC, NHANES III)...
  47. Viral Hepatitis C and Lipid Homeostasis
    Aleem Siddiqui; Fiscal Year: 2012
    ..Hepatic steatosis (fatty liver) is recognized as a common histologic feature of chronic hepatitis C and occurs at an average rate of 50%...
  48. Optimizing Patient-Oriented Outcomes for Chronic Hepatitis C
    Mai Tuyet Pho; Fiscal Year: 2013
    PROJECT SUMMARY / ABSTRACT As treatment regimens for chronic hepatitis C evolve at a rapid pace, the decision to treat immediately or defer for the promise of future therapy has become increasingly complex...
  49. Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL)
    James Burton; Fiscal Year: 2013
    ..We propose to continue the LADR-A2ALL protocol for pre-transplant antiviral treatment of patients with chronic hepatitis C in order to prevent recurrence of hepatitis C in the allograft post-transplant...
  50. Viral Associated Liver Disease Phase III
    Alexander Monto; Fiscal Year: 2013
    ..In the proposed study, we will examine long-term clinical outcomes in treated and untreated patients with chronic hepatitis C virus (HCV) infection. Currently, 5...
  51. CAM Herbal Cocktails for Boosting Antioxident Activity to Treat Liver Disease
    Roy L Hawke; Fiscal Year: 2010
    ..More than 50% of patients with chronic hepatitis C either have contraindications or do not achieve sustained virological response to therapy and would ..
  52. Structure and function of the HCV RNA replicase
    Charles M Rice; Fiscal Year: 2013
    ..individuals at risk for the development of cirrhosis, hepatocellular carcinoma, and liver failure, making chronic hepatitis C the leading indication for liver transplantation...
  53. The Lysosomal-Mitochondrial Axis in Nonalcoholic Fatty Liver Disease
    Ariel Feldstein; Fiscal Year: 2011
    ..in non-adipose tissues has been implicated in the pathogenesis of other human liver diseases including chronic hepatitis C infection, alcoholic steatohepatitis and hemochromatosis, as well as other diseases such as type II ..
  54. Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users
    LYNN ERICA TAYLOR; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) is a significant public health problem and leading cause of liver failure and death for HIV(+) populations in the U.S...
  55. Mentoring Junior Faculty: Viral hepatitis Clinical Research
    Michael W Fried; Fiscal Year: 2013
    ..Over the last decade, significant progress has occurred in the development of new treatments for chronic hepatitis C and hepatitis B, although management strategy of these diseases continues to evolve...
  56. Type 1 IFN Function and Signaling in Immunity to Viruses
    CHRISTINE ANNE BIRON; Fiscal Year: 2013
    ..Because type 1 IFNs are also being used, with uneven success, in the treatments of cancer, chronic hepatitis C virus infections, and multiple sclerosis, and ablation protocols are being developed to block their ..
  57. Genetic viral and host adaptations to breach species barriers of HCV
    Alexander Ploss; Fiscal Year: 2013
    ..At least 130 million individuals suffer from chronic hepatitis C, which is caused by hepatitis C virus (HCV) - a positive sense, single-stranded RNA virus of the ..
  58. HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*
    Lennox Jeffers; Fiscal Year: 2005
    ..interferon alfa-2a (Peginterferon alfa-2a) in combination with Ribavirin in the treatment of genotype-1 chronic hepatitis C (HCV, genotype-1) in African American men and women as compared to non-Hispanic whites...
  59. PROTEOMICS AND HEPATITIS C: FIBROSIS AND PROGNOSIS
    Glenn Gourley; Fiscal Year: 2005
    Liver fibrosis is an important factor in the progression of disease for millions of people with chronic hepatitis C. There is a fundamental gap in understanding the development of liver fibrosis in people with chronic hepatitis C which ..
  60. EXPERIMENTAL MODELS AND CLINICAL VIROLOGY OF HEPATITIS C
    Nelson Fausto; Fiscal Year: 1999
    ..HCV infection is characterized by persistent viremia and often progressive liver disease. Chronic hepatitis C is the most common indication for liver transplantation in adults, and at the University of Washington ..
  61. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    DESCRIPTION (adapted from the application) Current treatment options for chronic hepatitis C infection remain limited and unsatisfactory...
  62. Resistance to Antiviral Therapy in Chronic Hepatitis C
    Norah Terrault; Fiscal Year: 2005
    An estimated 600,000 African-Americans have chronic hepatitis C virus (HCV) infection, representing 22% of the total infected population in the U.S...
  63. HEPATITIS C IN CLINICALLY DISCORDANT HEMOPHILIC SIBLINGS
    Michael Fried; Fiscal Year: 2002
    ..clinical spectrum of hepatitis C is variable and the factors responsible for these divergent outcomes with chronic hepatitis C infection remain unknown...
  64. Targeting pDCs for the Generation of Effective Anti-HCV CD8+ T-Cell Immunity
    John Connolly; Fiscal Year: 2009
    ..There is a need for novel therapeutic approaches to the treatment of chronic hepatitis C infection...
  65. Racial Differences in IFN Transcriptional Response
    Daryl Lau; Fiscal Year: 2009
    DESCRIPTION (provided by the applicant): Chronic hepatitis C virus (HCV) is one of the most prevalent diseases of the liver in the United States...
  66. STUDIES OF THE NATURAL HISTORY OF HEPATITIS C IN LIVER
    Robert Carithers; Fiscal Year: 2002
    b>Chronic hepatitis C virus infection has emerged as the most important form of viral hepatitis in the United States...